FDA To Follow EMEA's Lead: ODAC Votes To Require Randomized Controlled Trials For Future Cutaneous T-Cell Lymphoma Drug Approval

FDA may soon follow the European Medicine Agency's lead in approval standards for cutaneous T-cell lymphoma drugs by requiring randomized clinical trials for future drug development